-
公开(公告)号:US08232292B2
公开(公告)日:2012-07-31
申请号:US12216257
申请日:2008-07-01
IPC分类号: A61K31/47 , C07D401/02
CPC分类号: C07D401/12
摘要: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.
摘要翻译: (S)-1-(4-氯-5-异喹啉磺酰基)-3-(甲基氨基)吡咯烷一盐酸盐及其结晶,以及上述一盐酸盐的结晶,在一个或多个位置上具有主峰或峰 由粉末X射线衍射光谱中的2和等级为13.9°,21.5°,21.7°,22.4°,22.8°,24.5°和35.0°的位置组成,其作为预防药物的活性成分具有优异的性质 和/或治疗性青光眼等。
-
公开(公告)号:US20090156823A1
公开(公告)日:2009-06-18
申请号:US12216257
申请日:2008-07-01
IPC分类号: C07D217/22
CPC分类号: C07D401/12
摘要: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.
摘要翻译: (S)-1-(4-氯-5-异喹啉磺酰基)-3-(甲基氨基)吡咯烷一盐酸盐及其结晶,以及上述一盐酸盐的结晶,在一个或多个位置上具有主峰或峰 包括在粉末X射线衍射光谱中2θ为13.9°,21.5°,21.7°,22.4°,22.8°,24.5°和35.0°的位置,其作为用于预防和/ 或治疗青光眼等。
-
公开(公告)号:US08299055B2
公开(公告)日:2012-10-30
申请号:US12571601
申请日:2009-10-01
IPC分类号: C07D401/12 , A61K31/47
CPC分类号: C07D401/12 , C07D217/02 , C07D401/10 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要: The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
摘要翻译: 本发明涉及由下式(1)表示的化合物:其中D1,A1,D2,R1,D3和R2各自具有与本说明书中定义的相同的含义或其盐。 由式(1)表示的化合物或其盐具有IKK&bgr; 抑制活性等,并且可用于预防和/或治疗IKK和相关疾病或症状等。
-
公开(公告)号:US20120270898A1
公开(公告)日:2012-10-25
申请号:US13535116
申请日:2012-06-27
申请人: Hitoshi KIDA , Koki Matsubara , Shunsuke Kaneko
发明人: Hitoshi KIDA , Koki Matsubara , Shunsuke Kaneko
IPC分类号: C07D401/12 , A61P27/02 , A61P27/06 , A61K31/4725
CPC分类号: C07D401/12
摘要: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.
摘要翻译: (S)-1-(4-氯-5-异喹啉磺酰基)-3-(甲基氨基)吡咯烷一盐酸盐及其结晶,以及上述一盐酸盐的结晶,在一个或多个位置上具有主峰或峰 由粉末X射线衍射光谱中的2和等级为13.9°,21.5°,21.7°,22.4°,22.8°,24.5°和35.0°的位置组成,其作为预防药物的活性成分具有优异的性质 和/或治疗性青光眼等。
-
公开(公告)号:US20100261701A1
公开(公告)日:2010-10-14
申请号:US12571601
申请日:2009-10-01
IPC分类号: A61K31/4725 , C07D401/12 , C07D409/14 , A61K31/496 , C07D401/14 , A61K31/501 , C07D413/14 , A61K31/5377 , A61K31/506 , C07D405/14 , C07D401/10 , C07D417/14 , A61P29/00 , A61P35/00 , A61P37/06
CPC分类号: C07D401/12 , C07D217/02 , C07D401/10 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要: The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
摘要翻译: 本发明涉及由下式(1)表示的化合物:其中D1,A1,D2,R1,D3和R2各自具有与本说明书中定义的相同的含义或其盐。 由式(1)表示的化合物或其盐具有IKK&bgr; 抑制活性等,并且可用于预防和/或治疗IKK和相关疾病或症状等。
-
公开(公告)号:US08664243B2
公开(公告)日:2014-03-04
申请号:US13535116
申请日:2012-06-27
申请人: Hitoshi Kida , Koki Matsubara , Shunsuke Kaneko
发明人: Hitoshi Kida , Koki Matsubara , Shunsuke Kaneko
IPC分类号: C07D401/12 , A61K31/47
CPC分类号: C07D401/12
摘要: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.
摘要翻译: (S)-1-(4-氯-5-异喹啉磺酰基)-3-(甲基氨基)吡咯烷一盐酸盐及其结晶,以及上述一盐酸盐的结晶,在一个或多个位置上具有主峰或峰 包括在粉末X射线衍射光谱中2thetas为约13.9°,21.5°,21.7°,22.4°,22.8°,24.5°和35.0°的位置,其作为用于预防和/ 或治疗青光眼等。
-
-
-
-
-